Active, not recruitingPHASE2, PHASE3NCT05432791
Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
Studying Leiomyosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Matthew InghamAlliance for Clinical Trials in Oncology
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 73 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2027
Study locations (30)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- Alaska Women's Cancer Care, Anchorage, Alaska, United States
- Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Epic Care-Dublin, Dublin, California, United States
- Epic Care Partners in Cancer Care, Emeryville, California, United States
- City of Hope at Irvine Lennar, Irvine, California, United States
- Contra Costa Regional Medical Center, Martinez, California, United States
- Epic Care Cyberknife Center, Walnut Creek, California, United States
- UCHealth University of Colorado Hospital, Aurora, Colorado, United States
- UCHealth Memorial Hospital Central, Colorado Springs, Colorado, United States
- Memorial Hospital North, Colorado Springs, Colorado, United States
- Poudre Valley Hospital, Fort Collins, Colorado, United States
- Cancer Care and Hematology-Fort Collins, Fort Collins, Colorado, United States
- UCHealth Greeley Hospital, Greeley, Colorado, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05432791 on ClinicalTrials.govOther trials for Leiomyosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07125183Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic LeiomyosarcomaUniversity of Colorado, Denver
- ENROLLING BY INVITATIONNANCT07405346A Trial for Advanced Leiomyosarcoma With Human Organoid-guided Personalized EfficacyUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE1NCT06957431Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and LeiomyosarcomaWashington University School of Medicine
- RECRUITINGPHASE2NCT07076186Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMSM.D. Anderson Cancer Center
- RECRUITINGPHASE2NCT06528769Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced LeiomyosarcomaGabriel Tinoco
- RECRUITINGPHASE2NCT06524583Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the TumourUNICANCER
- RECRUITINGPHASE2NCT06571734XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable LeiomyosarcomaNorthwestern University
- RECRUITINGPHASE1NCT06308419A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or DeletionsM.D. Anderson Cancer Center